Shen J, Hao S G, Chen B B, Wang C
Baoshan Branch of Shanghai First People's Hospital, Shanghai 200940, China.
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Zhonghua Xue Ye Xue Za Zhi. 2020 Feb 14;41(2):123-127. doi: 10.3760/cma.j.issn.0253-2727.2020.02.007.
To investigate the occurrence and influencing factors of anemia in lymphoma patients and its effect on treatment. A total of 501 lymphoma patients, who were hospitalized in four general hospitals in Shanghai from January 2017 to June 2018, were followed up for six months. The clinical data about anemia were collected and statistically analyzed. Among all the enrollment patients, there were 178 patients (35.5%) had anemia. Among 289 patients whom were initially treated for lymphoma, there were 99 patients (34.3%) with anemia. In the following-up time, there were 136 new cases (42.1%) of anemia. The total prevalence of anemia was 62.7%. The univariate analysis indicated that the anemia incidence for initially treated lymphoma patients was significantly related to their age, pathological type, bone marrow infiltration, IPI scores and Ann Arbor stage. The response to initially treatment in lymphoma patients with anemia was inferior to those without anemia. The multivariate analysis indicated that IPI scores 3-5 points (<0.001, =4.230, 95% 2.339-7.650) and chemotherapy treatment (<0.001, =11.049, 95% 5.149-23.711) were the independent influential factors to the emerging anemia incidence. PS score used to evaluate patient physical condition was obviously related to the anemia occurrence. Lymphoma patients have a high prevalence and incidence of anemia. The occurrence and severity of anemia are closely related to the efficacy and physical condition of lymphoma patients.
探讨淋巴瘤患者贫血的发生情况、影响因素及其对治疗的影响。选取2017年1月至2018年6月在上海4家综合医院住院的501例淋巴瘤患者，进行为期6个月的随访。收集并统计分析贫血的临床资料。所有入选患者中，178例（35.5%）有贫血。在289例初治淋巴瘤患者中，99例（34.3%）有贫血。在随访期间，有136例新发生贫血病例（42.1%）。贫血总患病率为62.7%。单因素分析表明，初治淋巴瘤患者的贫血发生率与年龄、病理类型、骨髓浸润、国际预后指数（IPI）评分及Ann Arbor分期显著相关。贫血淋巴瘤患者的初始治疗反应低于无贫血患者。多因素分析表明，IPI评分3 - 5分（<0.001，=4.230，95%可信区间2.339 - 7.650）和化疗治疗（<0.001，=11.049，95%可信区间5.149 - 23.711）是贫血发生率的独立影响因素。用于评估患者身体状况的PS评分与贫血发生明显相关。淋巴瘤患者贫血患病率和发生率较高。贫血的发生及严重程度与淋巴瘤患者的疗效及身体状况密切相关。
